Orlistat is an obesity treatment drug that also reduces the risk factors associated with obesity. Orlistat inactivates lipase by binding to lipase residues and inhibits lipase in the gastrointestinal tract to promote the elimination of fat from the body. It is mainly used in patients with excessive obesity, and belongs to a kind of obesity treatment drug that does not act on the central nervous system. Adverse reactions are mainly gastrointestinal reactions, including abdominal pain, steatorrhea, fecal incontinence, etc. Other systemic adverse reactions include respiratory tract infections and headache. It is contraindicated in patients who are allergic to the drug or have chronic malabsorption syndrome and cholestasis. The use of the drug should be under the supervision of a doctor, and should not be used without authorization.